Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• The RAF-MEK1/2-ERK1/2 pathway is crucial in cancer, often deregulated by mutations in RAS or BRAF.
• Approved RAF and MEK1/2 inhibitors exist, with ERK1/2 inhibitors (ERKi) in clinical trials.

Purpose of the Study:

• To characterize the mechanisms of action (MoA) of five ERKi.
• To evaluate their functional consequences on ERK1/2 signaling, gene expression, and antiproliferative efficacy.

Main Methods:

• Characterization of five ERKi MoA.
• Assessment of ERK1/2 signaling, p-ERK1/2 nuclear accumulation, gene expression, and antiproliferative effects in cancer cell lines.

Main Results:

• Catalytic ERKi led to p-ERK1/2 nuclear accumulation in KRAS-mutant cells.
• Dual-mechanism ERKi blocked ERK1/2 phosphorylation by MEK1/2, preventing nuclear entry.
• Dual-mechanism ERKi demonstrated superior potency, durable pathway inhibition, and enhanced gene expression suppression.

Conclusions:

• Dual-mechanism ERKi exhibit enhanced efficacy in BRAF- and RAS-mutant cell lines compared to catalytic ERKi.
• Blocking ERK1/2 phosphorylation and nuclear translocation is key for potent antiproliferative effects.
• ERKi MoA significantly impacts biological activity and therapeutic potential in cancer treatment.